Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
BRANFORD, Conn., April 28, 2026 (GLOBE NEWSWIRE) -- EvolveImmune Therapeutics, a clinical-stage immuno-oncology company developing a new class of multi-specific T cell engagers with integrated CD2...
-
Asgard Therapeutics to present advanced preclinical data on its lead asset AT-108, a first-in-class, off-the-shelf cancer immunotherapy, at ASGCT 2026
-
With AI tools demonstrating 85–95% accuracy in biomarker identification and attracting more than $3 billion in recent funding.
-
Siren Biotechnology Publishes Foundational AAV Immuno-Gene Therapy Data and Announces Presentations at ASGCT 2026
-
EXECUTIVE SUMMARY final European scientific advice received for pivotal Phase III vitiligo studyEMA emphasised its “totality of evidence” approachcentral photographic review and validated disease...
-
IBA réunit les experts les plus renommés en protonthérapie venant des institutions de soins oncologiques les plus prestigieuses. Louvain-la-Neuve, Belgique, le 24 avril 2026 – IBA (Ion Beam...
-
IBA gathers the most knowledgeable proton therapy experts coming from the most prestigious cancer care institutions. Louvain-La-Neuve, Belgium, April 24, 2026 – IBA (Ion Beam Applications S.A.,...
-
AI-driven monitoring is increasingly used to improve precision, efficiency, and safety in spine, neurosurgical, and ENT procedures.
-
Exicure enters co-development agreement with Adbiotech to advance Burixafor (GPC-100) combination therapies across multiple indications.
-
Positive results from “LAPNET-01,” phase 1b trial of NP137 in patients with pancreatic ductal adenocarcinoma, published in Nature.